A Study of ARRY-382 in Patients With Selected Advanced or Metastatic Cancers

Array BioPharma

Status and phase

Completed

Phase 1

Conditions

Metastatic Cancer

Treatments

Drug: ARRY-382, cFMS inhibitor; oral

Study type

Interventional

Funder types

Industry

Identifiers

NCT01316822

ARRAY-382-101

Details and patient eligibility

About

This is a Phase 1 study during which patients with advanced cancer will receive investigational study drug ARRY-382. Patients will receive increasing doses of study drug in order to achieve the highest dose of the study drug possible that will not cause unacceptable side effects. Patients will be followed to see what side effects and effectiveness the study drug has, if any, in treating the cancer. Approximately 50 patients from the US will be enrolled in this study.

Enrollment

26 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Key Inclusion Criteria:

A histologically or cytologically confirmed diagnosis of advanced or metastatic solid cancer refractory to standard treatment, for which no standard therapy is available or for which the patient refuses standard therapy.
Measurable disease or evaluable, nonmeasurable disease.
Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1 or 2.
Hemoglobin ≥ 9.0 g/dL, ANC > 1500/uL and platelet count ≥ 100,000/uL.
AST/serum glutamic oxaloacetic transaminase (SGOT) and ALT/serum glutamic pyruvic transaminase (SGPT) ≤ 2.5 × the upper limit of normal (ULN).
Bilirubin ≤ ULN.
Serum creatinine ≤ 1.5 × ULN.
Potassium, magnesium and calcium (corrected calcium when serum albumin levels are abnormal) within the normal range.
Additional criteria exist.

Key Exclusion Criteria:

12-lead ECG demonstrating a mean QTcF > 450 msec (triplicate assessment) at the Screening Visit or history/evidence of long QT syndrome.
History of acute coronary syndromes, including unstable angina, coronary angioplasty, or stenting, within the past 24 weeks.
Use of concomitant medications that prolong the QT/QTc interval, as assessed by the Investigator, within 14 days prior to first dose of study drug.
Use of concomitant medication that is a strong CYP3A inhibitor or inducer within 14 days prior to first dose of study drug.
Class II, III or IV heart failure as defined by the New York Heart Association (NYHA) functional classification system.
Uncontrolled or symptomatic brain metastases (if a patient has brain metastases and is on steroids, the steroid dose must have been stable for at least 30 days).
Active refractory nausea and vomiting, chronic gastrointestinal diseases (e.g., inflammatory bowel disease) or significant bowel resection that, in the judgment of the Investigator, would preclude adequate absorption (a previous Whipple procedure is allowed).
Additional criteria exist.